"Founded in 2007, The Oncology Institute of Hope and Innovation is dedicated to excel in cancer prevention, diagnosis and education. As the largest private practice cancer center in California, The Oncology Institute continues to provide extensive services including state-of-the-art infusion centers, chemotherapy educational sessions, in-house support groups, dietary and nutritional counseling, in-house pharmacy, financial counseling, clinical trials, comprehensive lab testing, and end of life counseling."

During the past decade, The Oncology Institute of Hope and Innovation conducted 48 clinical trials. In the 10-year time frame, 48 clinical trials started and 20 clinical trials were completed, i.e. on average, 41.7% percent of trials that started reached the finish line to date. In the past 5 years, 22 clinical trials started and 16 clinical trials were completed. i.e. 72.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Oncology Institute of Hope and Innovation" #1 sponsor was "Pfizer" with 7 trials, followed by "G1 Therapeutics, Inc." with 3 trials sponsored, "Takeda" with 3 trials sponsored, "ADC Therapeutics S.A." with 2 trials sponsored and "Clovis Oncology, Inc." with 2 trials sponsored. Other sponsors include 28 different institutions and companies that sponsored additional 33 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Oncology Institute of Hope and Innovation" #1 collaborator was "ARMO BioSciences" with 2 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Axis Clinicals Limited" with 1 trials as a collaborator, "BeiGene, Ltd." with 1 trials as a collaborator and "Belgium and Luxembourg Gynaecological Oncology Group" with 1 trials as a collaborator. Other collaborators include 9 different institutions and companies that were collaborators in the rest 19 trials.

According to Clinical.Site data, the most researched conditions in "The Oncology Institute of Hope and Innovation" are "Carcinoma, Non-Small-Cell Lung" (3 trials), "Multiple Myeloma" (3 trials), "Non Small Cell Lung Cancer" (3 trials), "Follicular Lymphoma" (2 trials) and "Hematological Malignancies" (2 trials). Many other conditions were trialed in "The Oncology Institute of Hope and Innovation" in a lesser frequency.

Most popular intervention types in "The Oncology Institute of Hope and Innovation" are "Drug" (46 trials), "Biological" (6 trials), "Other" (2 trials), "Diagnostic Test" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Dexamethasone" (4 trials), "Gemcitabine" (4 trials), "Cisplatin" (3 trials) and "Rituximab" (3 trials). Other intervention names were less common.

The vast majority of trials in "The Oncology Institute of Hope and Innovation" are 47 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "The Oncology Institute of Hope and Innovation". undefined are not yet recruiting, 12 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in The Oncology Institute of Hope and Innovation, undefined suspended trials, and 14 terminated clinical trials to date.

Out of the total trials that were conducted in The Oncology Institute of Hope and Innovation, 13 "Phase 1" clinical trials were conducted, 23 "Phase 2" clinical trials and 21 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".